Skip to main content
. 2013 May 2;178(4):610–624. doi: 10.1093/aje/kwt007

Table 3.

Associations of OBS Measures With Incident, Sporadic Colorectal Adenoma in Data From 3 Case-Control Studies (CPRU Study, 1991–1994; MAP I Study, 1994–1997; and MAP II Study, 2002)

OBSa CPRU Study
MAP Studies
Pooled Data
No. of Cases RRb 95% CI No. of Cases RRb 95% CI No. of Cases RRb 95% CI
OBS–equal weight  
 Tertile 1 258 1.00 Referent 102 1.00 Referent 360 1.00 Referent
 Tertile 2 182 0.68 0.53, 0.87 65 0.67 0.43, 1.07 247 0.67 0.54, 0.83
 Tertile 3 124 0.51 0.39, 0.68 58 0.67 0.41, 1.09 182 0.54 0.43, 0.69
  Ptrend <0.0001 0.09 <0.0001
OBS–lit. review  
 Tertile 1 301 1.00 Referent 141 1.00 Referent 442 1.00 Referent
 Tertile 2 150 0.62 0.47, 0.81 36 0.32 0.19, 0.53 186 0.53 0.42, 0.67
 Tertile 3 113 0.47 0.35, 0.64 48 0.44 0.27, 0.73 161 0.45 0.35, 0.58
  Ptrend <0.0001 <0.001 <0.0001
OBS–a posteriori  
 Tertile 1 299 1.00 Referent 122 1.00 Referent 421 1.00 Referent
 Tertile 2 164 0.57 0.44, 0.74 66 0.56 0.36, 0.88 230 0.57 0.46, 0.71
 Tertile 3 101 0.40 0.30, 0.53 37 0.34 0.21, 0.57 138 0.38 0.29, 0.49
  Ptrend <0.0001 <0.0001 <0.0001
OBS–Bayesian  
 Tertile 1 305 1.00 Referent 139 1.00 Referent 444 1.00 Referent
 Tertile 2 150 0.57 0.43, 0.73 35 0.27 0.16, 0.46 185 0.47 0.38, 0.60
 Tertile 3 109 0.45 0.34, 0.60 51 0.47 0.29, 0.76 160 0.45 0.35, 0.58
  Ptrend <0.0001 <0.001 <0.0001

Abbreviations: CI, confidence interval; CPRU, Cancer Prevention Research Unit; MAP, Markers of Adenomatous Polyps; OBS, oxidative balance score; RR, relative risk.

a OBS–equal weight: all OBS components received equal weights; OBS–lit. review: weights for OBS components were based on effect estimates derived from literature review; OBS–a posteriori: weights for OBS components were based on CPRU Study data; OBS–Bayesian: weights for OBS components were based on Bayesian analysis of case-control data. Tertiles for OBS are sex-specific, and the dietary components were adjusted for total energy intake.

b Adjusted for age, sex, education, family history of colorectal cancer in a first-degree relative, regular aspirin use, regular use of nonsteroidal antiinflammatory drugs, total calcium intake, total vitamin D intake, total energy intake, total folate intake, dietary fiber intake, and hormone therapy (among women).